The accumulation of major driver alterations in pancreatic cancer, including CDKN2A, KRAS, p53 and SMAD4, is inversely associated with disease-free survival (DFS) and overall survival (OS), indicating a higher mortality risk with an increasing number of altered genes. This evidence concerns the gene KRAS and familial pancreatic carcinoma.